CAPR רווח נקי למניה ב-12 החודשים האחרונים capricor.com

Chart volatility is driven by fierce competition in the cell therapy sector and the risks associated with genetic innovations. The financial foundation relies on the closed-loop cycle of the Capricor Therapeutics (CAPR) CAP-1002 platform and the modernization of plants to increase drug synthesis. The annual net income per share trend demonstrates current dynamics, where the value of -2.65 reflects the balance of the asset yield metric.

Capricor Therapeutics (CAPR) investments in the development of cell technologies to combat Duchenne muscular dystrophy define its profit profile, where R&D expenses directly impact the bottom line. Analyzing annual net income per share allows for an assessment of the business's real equity yield, adjusted for issuance volume, which helps investors identify the company's fundamental stability through the price action on this chart.